NIH Staff Present at BIO
During BIO's 2013 Annual Meeting, NIH staff will participate in many sessions as chairs, discussants, and speakers.
To see the NIH at BIO schedule click here:
SESSIONS FEATURING NIH STAFF
Monday, April 22Add to Outlook Calendar
9th Annual Biotechnology Entrepreneurial Boot camp
2:30 p.m. – 3:30 p.m.
Location: 6403 B
- Steve Fergusson, (Speaker), Office of Technology Transfer, NIH, Bethesda, MD
Biotechnology Entrepreneurship Boot Camp is an intensive program that walks you through the necessary steps and gives you the skills to transform technology and invention into a viable company.
Since its debut in 2005, the Boot Camp has evolved to address a broad range of issues faced by entrepreneurs from the managerial, scientific and academic communities. You will develop the insight and energy required for entrepreneurial success as you learn to:
- Think strategically in selecting and managing projects.
- Plan for expeditious and cost-effective management.
- Understand the requirements of all the involved stakeholders.
- Oversee the essential components of the commercialization process.
Each year, faculty from the event's host region bring fresh insights to the program, while a core faculty returns to present material that has proven effective throughout the years. Historically, this core has included the Boot Camp founder and co-chair, Professor Arthur Boni of the Tepper School of Carnegie Mellon University; Professor Stephen Sammut of the Wharton School and Burrill & Company.
Tuesday, April 23Add to Outlook Calendar
Selected NIH Initiatives to Promote Drug Discovery and Development—
NCI, NINDS, and NCATS
9:00 a.m. – 10:15 a.m.
- Lu Wang, (Speaker), National Human Genome Research Institute, NIH, Bethesda, MD
Many of the world's 6,000 to 8,000 rare diseases are chronic, progressive, and often life-threatening, but few can be treated effectively—or even diagnosed reliably and early enough for best therapeutic outcomes. The International Rare Diseases Research Consortium (IRDiRC), launched in 2011 by the European Commission and the U.S. National Institutes of Health, unites public and private funders and coordinates research efforts toward an ambitious goal: develop 200 new therapies and means to diagnose most rare diseases by 2020.
- Describe how IRDiRC and its partner organizations operate in an international arena
- Attract interested organizations (pharmaceutical, diagnostics companies, and research investors)
- Present the opportunities and challenges of developing drugs and diagnostics for rare diseases
Add to Outlook Calendar
Open Innovation: Transforming the Model of Biopharmaceutical R&D
2:30 p.m. – 3:30 p.m.
Location: S401 BC
- Christopher Austin (Speaker), National Center for Advancing Translational Science, NIH, Bethesda, MD
In order to help accelerate the time and reduce the cost between concept and cure, a number of new R&D initiatives are emerging. These efforts aim to bring medicines to patients faster by facilitating collaboration to solve common challenges encountered during the discovery and development process. This Super Session will focus on several of these recently-created public and private sector partnerships whose goal is to improve the productivity of the biomedical research ecosystem, and will explore how they may provide solutions with measurable impact for patients worldwide.
Wednesday, April 24Add to Outlook Calendar
Using NIH Resources to Help Advance Biomedical Technology and Drug Projects to Industry Adoption
9:00 a.m. – 10:15 a.m.
Location: N427 BC
- Eric Nelson (Moderator),National Institutes of Neurological Diseases and Stroke, NIH, Bethesda, MD
- Rajesh Ranganathan (Speaker), National Institutes of Neurological Diseases and Stroke, NIH, Bethesda, MD
- Kathleen Rousche (Speaker), National Heart, Lung, and Blood Institute, NIH, Bethesda, MD
- Nora Yang (Speaker), National Center for Advancing Translational Science, NIH, Bethesda, MD
Biotechnology companies and university researchers urgently need additional funding and research resources to move technologies and therapeutic programs to industry adoption (i.e. investor funding and corporate partnerships). During the last year, the NIH has launched and expanded several innovative programs to support technology development in response to this need. A panel of program leaders from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders & Stroke (NINDS), and National Center for Advancing Translational Sciences (NCATS) will provide an overview of these programs, including their intellectual property and financial frameworks, and how their processes can lead to successful technology development outcomes. This session will provide a rare opportunity to ask questions to better understand how to successfully leverage these valuable NIH resources.
- Explore the biomedical technology development, therapeutic and device resources at the NIH
- Identify cutting-edge approaches to translational research and public-private partnerships
- Assess financial strategies for biotechnology venture capitalists and small biotechnology companies